DOCSLIB.ORG

Molecular Remission and Reconstitution of a Full Chimera With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Remission and Reconstitution of a Full Chimera With Correspondence 2455 neurotoxicity.2–3 The CSF clearance of ara-C is similar to that of the CSF bulk flow rate. Furthermore, there is little conversion of ara-C to uracile arabinoside in the brain and CSF. Thus, the obstructed CSF flow due to the massive number of leukemic cells and their lysis could result in a high CSF concentration of ara-C and/or a prolonged exposure of cerebellum to ara. C. Unfortunately, the methotrexate or ara-CTP levels were not measured in the patient’ CSF. To our knowl- edge, neurotoxicity due to intrathecal ara-C has not been previously reported. This observation confirms that protocols for overt meningeal leukemia should be designed with lower rather than higher dosages of intrathecal drugs, not only for methotrexate but also for ara-C. We would like to caution against the systematic use of ara-C in the initial intrathecal treatment of these overt CNS leukemias. F Legrand11Service d’He´matologie, Hopital Robert Debre´, S Dorgeret2 Paris, France; 2Service de Radiologie, Hopital C Saizou3 Robert Debre´, Paris, France; 3Service de M Duval1 Reanimation, Hopital Robert Debre´, Paris, France E Vilmer1 References 1 Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave´ H, Thyss A, Benoit Figure 3 MR imaging performed 2 days after the last CT coronal Y, Fournier M, Souillet G, Robert A, Nelken B, Millot F, Lutz P, T2-weighted sequence. The cerebellum is still enlarged, and shows Railland X, Mechinaud F, Boutard P, Behar C, Chantraine J-M, hyperintensity of the cortex, due to oedema (?). Plouvier E, Laurreys G, Brock P, Uyttebroeck A, Margueritte G, Plantaz D, Norton L, Francotte N, Gyselinck J, Waterkeyn C, Solbu G, Philippe N, Otten J. Long-term follow up of three randomized preparation used for the intrathecal treatment was checked (100 mg trials (58831, 58832, 58881) in childhood acute lymphoblastic with 5 ml of solvent) and the dose (1.6 ml for 30 mg) administered leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257– was correct. 2266. The mechanisms involved in this CNS toxicity could be toxic 2 Balis FM, Poplack DG. Central nervous system pharmacology of exposure of the cerebellum to ara-C. As has been suggested for metho- antileukemic drugs. Am J Pediat Hemat 1989; 11: 74–86. trexate, the presence of overt meningeal leukemia may predispose to 3 Pochedly C. Neurotoxicity due to CNS therapy for leukemia. Med the increased CSF concentration of ara-C and to the development of Pediatr Oncol 1977; 3: 101–115. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation Leukemia (2002) 16, 2455–2456. doi:10.1038/sj.leu.2402716 plete remission after induction treatment with a persistence of the tran- script at the RT-PCR. The molecular complete remission was obtained TO THE EDITOR after the second consolidation therapy. After 12 months from CR, 8 months from the PML/RAR␣ negativity, Recently, the therapeutic effect of arsenic trioxide (As2O3) has been while on maintenance therapy with alternating methotrexate, 6-mer- proven in acute promyelocytic leukemia (APL) patients in relapse and captopurine, and all-trans retinoic acid (ATRA) according to the proto- at diagnosis by several groups in China.1 On the basis of the impress- col, the patient showed a molecular relapse of the disease detected ive results obtained in the pilot trial of the Memorial Sloan-Kettering in two bone marrow samples collected 3 weeks apart. He received Cancer Center,2 92% complete remission (CR) rate in relapsed APL ATRA for 1 month as salvage treatment followed by chemotherapy patients, in the United States a multicenter study has been conducted with mitoxantrone and high-dose Ara-C for 4 consecutive days. As to evaluate the efficacy and tolerability of As2O3 for remission induc- soon as a second molecular remission was achieved he underwent tion and consolidation in a larger population of APL patients who had allogeneic bone marrow transplantation from an HLA-identical relapsed from prior retinoic and anthracycline-based chemotherapy.3 brother. The conditioning treatment consisted of cyclophosphamide In this study the authors reported an 85% CR rate with a relapse free and TBI; cyclosporine and short-term methotrexate were administered survival rate at 18 months of 56%. for graft-versus-host disease (GVHD) prophylaxis. The clinical course Here, we report a patient with APL who was treated with As2O3 was unremarkable, the patient did not experience acute or chronic while in second relapse after allogeneic bone marrow transplantation. GVHD and cyclosporine was slowly tapered until discontinuation at The patient, a 53-year-old male, was diagnosed in July 1998 with the 7th month. At the posttransplant restaging, 3 months after bone APL, at diagnosis cytogenetic showed a normal karyotype while with marrow reinfusion, he was in complete hematological and molecular reverse transcriptase polymerase chain reaction (RT-PCR) assay a remission and bone marrow showed a complete donor chimerism. PML/RAR␣ transcript with a bcr3 isoform was identified. The patient Eleven months from transplant a second relapse occurred, bone was treated according to the GIMEMA AIDA trial4 reaching a com- marrow trephine showing the presence of a diffuse interstitial infil- tration of abnormal promyelocytes. Conventional cytogenetic analysis revealed 46,XY while the PML/RAR␣ fusion gene was detected both Correspondence: A Tedeschi, Divisione di Ematologia, Ospedale Nig- at RT-PCR and interphase FISH analysis. A mixed chimerism was dem- uarda Ca’Granda, Piazza dell’Ospedale Maggiore, Milano Italy; onstrated in the bone marrow mononuclear cell sample, with 50% of Fax: +390264442033 host cells. The peripheral blood examination revealed a WBC Received 11 June 2002; accepted 21 June 2002 5.7 × 109/l; Hb 11 g/dl, platelets 84 × 109/l; no blasts were observed in the peripheral blood smears. Leukemia Correspondence 2456 After written informed consent was obtained the patient received conversion to complete donor chimerism to be obtained. The patient As2O3 as salvage treatment, the drug being administered at the dosage did not experience myelosuppression and GVHD was not observed of 10 mg daily for 40 days. To prevent the development of symptoms during the reconstitution of donor bone marrow chimerism. identical to the retinoic acid syndrome, dexamethasone at the dosage Finally, a body of life-threatening adverse events has been fre- of 25 mg/day was added in the first 10 days of treatment. quently reported during treatment with As2O3; the tolerance to ther- Bone marrow aspirate performed after 15 days from the beginning apy in our case was impressive without any sign of toxicity. of treatment, to assess drug efficacy, showed the disappearance of visible leukemic cells while the PML/RAR␣ transcript persisted. The A Tedeschi11Division of Hematology, Niguarda Ca’ patient did not experienced extra-haematological toxicity. As regards R Cairoli1 Granda Hospital Milano, Italy; 2Division hematological toxicity we observed a transient grade 1 neutropenia, P Marenco1 of Hematology, San Bortolo Hospital according to WHO criteria, and a grade 2 thrombocytopenia; the A Nosari1 Vicenza, Italy patient showed complete platelet recovery within 10 days from ther- E Tresoldi1 apy discontinuation. The bone marrow evaluation at the end of treat- E Di Bona1 ment confirmed the morphological CR, PML/RAR␣ was not detected M Montillo1 by RT-PCR, and a fully donor chimerism was restored. The patient E Morra1 was consolidated with additional two courses of As2O3 for 25 days at the same dosage of 10 mg/day every 2 months without any hemato- logical or extrahematological toxicity. After 14 months the patient is still in a third morphological and References molecular remission maintaining complete donor chimerism. The analysis of the clinical history of this patient shows that the 1 Shen ZX, Chen CQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang best salvage treatment approach was difficult to establish since he had W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma already received an allogeneic bone marrow transplant. J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic Donor lymphocyte infusion to induce a graft-versus-leukemia (GVL) trioxide (As2O3) in the treatment of acute promyelocytic leukemia effect is a feasible approach in patients relapsing after allogeneic bone (APL): II. Clinical efficacy and pharmacokinetics in relapsed marrow transplant. The role of this procedure in recurrent acute patients. Blood 1997; 89: 3354–3360. myeloid leukemias has not been well established and no data regard- 2 Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti ing the effect in APL have been reported. Furthermore, our patient LJ, Corso D, DeBlasio A, Gabrilove J, Scheineberg DA, Pandolfi would not have experienced any advantage from GVL reactivity after PP, Warrel RP Jr. Complete remission after treatment of acute pro- the allogeneic transplant. In fact, he did not develop GVHD after allo- myelocytic leukemia with arsenic trioxide. N Engl J Med 1998; geneic transplant, even if the possibility of a GVL effect cannot be 339: 1341–1348. excluded in the absence of GVHD for reactivity against unique leuke- 3 Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Cal- mia-associated antigens. In addition, the duration of the second CR leja E, Stone RM, Kalycio M, Scheinberg DA, Steinherz P, Sievers was shorter than the first one. EL, Coutre` S, Dahlberg S, Ellison R, Warrel RP. United States multi- Morbidity of salvage treatment with cytotoxic drugs is potentially center study of arsenic trioxide in relapsed acute promyelocytic elevated in such heavily pretreated patients, and in addition, intensive leukemia. J Clin Oncol 2001; 19: 3852–3860. chemotherapy could determine myelosuppression of the residual 4 Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernas- donor marrow.
Load more

Recommended publications
  • A Systematic Review of the Effectiveness of Docetaxel and Mitoxantrone for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
    British Journal of Cancer (2006) 95, 457 – 462 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00 www.bjcancer.com A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer *,1 1 1 1 2 3 4 5 R Collins , R Trowman , G Norman , K Light , A Birtle , E Fenwick , S Palmer and R Riemsma 1 2 Centre for Reviews and Dissemination, University of York, Heslington, York YO10 5DD, UK; Rosemere Cancer Centre, Royal Preston Hospital, Sharoe 3 Green Lane North, Fulwood, Preston PR2 9HT, UK; Public Health & Health Policy, Division of Community Based Sciences, University of Glasgow, 4 5 1 Lilybank Gardens, Glasgow G12 8RZ, UK; Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK; Kleijnen Systematic Reviews Ltd, Westminster Business Centre, 10 Great North Way, Nether Poppleton, York YO26 6RB, UK Clinical Studies A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic hormone- refractory prostate cancer. Prednisone is not used in the UK, but it is reasonable to use docetaxel plus prednisone data in this review of docetaxel plus prednisolone) for the treatment of metastatic hormone-refractory prostate cancer. A scoping search identified a trial of docetaxel plus prednisone vs mitoxantrone plus prednisone, but did not identify any trials comparing docetaxel plus prednisolone/prednisone with any other treatments. Therefore, we considered additional indirect evidence that would enable a comparison of docetaxel plus prednisolone/prednisone with other chemotherapy regimens and active supportive care.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • NOVANTRONE (Mitoxantrone for Injection Concentrate) in Patients with Hepatic Insufficiency Is Not Established (See CLINICAL PHARMACOLOGY)
    NOVANTRONE® mitoXANTRONE for injection concentrate WARNING NOVANTRONE® (mitoxantrone for injection concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents. NOVANTRONE® should be given slowly into a freely flowing intravenous infusion. It must never be given subcutaneously, intramuscularly, or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. (See ADVERSE REACTIONS, General, Cutaneous and DOSAGE AND ADMINISTRATION, Preparation and Administration Precautions). NOT FOR INTRATHECAL USE. Severe injury with permanent sequelae can result from intrathecal administration. (See WARNINGS, General) Except for the treatment of acute nonlymphocytic leukemia, NOVANTRONE® therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving NOVANTRONE®. Cardiotoxicity: Congestive heart failure (CHF), potentially fatal, may occur either during therapy with NOVANTRONE® or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative NOVANTRONE dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In cancer patients, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m2. To mitigate the cardiotoxicity risk with NOVANTRONE, prescribers should consider the following: NOVANTRONE mitoXANTRONE for injection 1 All Patients: - All patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to start of NOVANTRONE® therapy.
    [Show full text]
  • How to Manage Acute Promyelocytic Leukemia
    Leukemia (2012) 26, 1743 -- 1751 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu HOW TO MANAGEy How to manage acute promyelocytic leukemia J-Q Mi, J-M Li, Z-X Shen, S-J Chen and Z Chen Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML). The prognosis of APL is changing, from the worst among AML as it used to be, to currently the best. The application of all-trans-retinoic acid (ATRA) to the induction therapy of APL decreases the mortality of newly diagnosed patients, thereby significantly improving the response rate. Therefore, ATRA combined with anthracycline-based chemotherapy has been widely accepted and used as a classic treatment. It has been demonstrated that high doses of cytarabine have a good effect on the prevention of relapse for high-risk patients. However, as the indications of arsenic trioxide (ATO) for APL are being extended from the original relapse treatment to the first-line treatment of de novo APL, we find that the regimen of ATRA, combined with ATO, seems to be a new treatment option because of their targeting mechanisms, milder toxicities and improvements of long-term outcomes; this combination may become a potentially curable treatment modality for APL. We discuss the therapeutic strategies for APL, particularly the novel approaches to newly diagnosed patients and the handling of side effects of treatment and relapse treatment, so as to ensure each newly diagnosed patient of APL the most timely and best treatment. Leukemia (2012) 26, 1743--1751; doi:10.1038/leu.2012.57 Keywords: acute promyelocytic leukemia (APL); all-trans-retinoic acid (ATRA); arsenic trioxide (ATO) INTRODUCTION In this review, we introduce the therapeutic strategies of APL, Acute promyelocytic leukemia (APL) is a distinct subtype of acute including the treatment of newly diagnosed and relapsed myeloid leukemia (AML) characterized by its abnormal promye- patients, as well as the ways to deal with the side effects.
    [Show full text]
  • Resistance to Antifolates
    Oncogene (2003) 22, 7431–7457 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc Resistance to antifolates Rongbao Zhao1 and I David Goldman*,1 1Departments of Medicine and Molecular, Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA The antifolates were the first class of antimetabolites to the kinetics of the interaction between MTX and DHFR enter the clinics more than 50 years ago. Over the was fully understood, and not until the late 1970s and following decades, a full understanding of their mechan- early 1980s when polyglutamate derivatives of MTX were isms of action and chemotherapeutic potential evolved detected and their pharmacologic importance clarified. along with the mechanisms by which cells develop Likewise, an understanding of tumor cell resistance to resistance to these drugs. These principals served as a antifolates evolved slowly, often paralleling the emergence basis for the subsequent exploration and understanding of of new molecular concepts. As the mechanisms of the mechanisms of resistance to a variety of diverse resistance to antifolates were characterized, this provided antineoplastics with different cellular targets. This section insights and principles that were broadly applicable to describes the bases for intrinsic and acquired antifolate other antineoplastics. Ultimately, this knowledge led to the resistance within the context of the current understanding development of a new generation of antifolates, in the late of the mechanisms of actions and cytotoxic determinants 1980s and 1990s, which are potent direct inhibitors of of these agents. This encompasses impaired drug transport tetrahydrofolate (THF)-cofactor-dependent enzymes. Sev- into cells, augmented drug export, impaired activation of eral of these drugs are now in clinical trials, and the antifolates through polyglutamylation, augmented hydro- activity of one, pemetrexed, has been confirmed in a large lysis of antifolate polyglutamates, increased expression Phase III trial (Vogelzang et al., 2003).
    [Show full text]
  • Methotrexate Cross-Resistance in a Mitoxantrone-Selected Multidrug-Resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-Dependent Drug Efflux1
    [CANCER RESEARCH 60, 3514–3521, July 1, 2000] Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux1 Erin L. Volk, Kristin Rohde, Myung Rhee, John J. McGuire, L. Austin Doyle, Douglas D. Ross, and Erasmus Schneider2 Wadsworth Center, New York State Department of Health, Albany, New York 12201 [E. L. V., K. R., M. R., E. S.]; Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York 12201 [E. L. V., E. S.]; Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263 [J. J. M.]; Greenbaum Cancer Center of the University of Maryland, Baltimore, Maryland 21201 [L. A. D., D. D. R.]; Department of Medicine, Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, Maryland 21201 [L. A. D., D. D. R.]; and Baltimore Veterans Medical Center, Department of Veterans Affairs, Baltimore, Maryland 21201 [D. D. R.] ABSTRACT resistance has been shown to be caused by decreased uptake attribut- able to the absence (2) of or defects (5, 6) in RFC1, reduced poly- Cellular resistance to the antifolate methotrexate (MTX) is often caused glutamylation either through decreased FPGS activity and/or expres- by target amplification, uptake defects, or alterations in polyglutamyla- sion (7), or enhanced ␥-GH activity and/or expression (8), and DHFR tion. Here we have examined MTX cross-resistance in a human breast carcinoma cell line (MCF7/MX) selected in the presence of mitoxantrone, overexpression (9) or mutation (10–12). an anticancer agent associated with the multidrug resistance (MDR) In contrast, a putative role for drug efflux in MTX resistance, phenotype.
    [Show full text]
  • Cladribine Injection
    PRODUCT MONOGRAPH PrCLADRIBINE INJECTION Solution for Intravenous Injection 1 mg/mL USP Antineoplastic / Chemotherapeutic Agent Fresenius Kabi Canada Ltd. Date of Revision: 165 Galaxy Blvd, Suite 100 June 9, 2015 Toronto, ON M9W 0C8 Control No.: 181078 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 3 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ......................................................................................................... 10 DOSAGE AND ADMINISTRATION ..................................................................................... 11 OVERDOSAGE ....................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 14 STORAGE AND STABILITY ................................................................................................
    [Show full text]
  • Cellular Pharmacology of Mitoxantrone in P
    Leukemia (1997) 11, 2066–2074 1997 Stockton Press All rights reserved 0887-6924/97 $12.00 Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines U Consoli, NT Van, N Neamati, R Mahadevia, M Beran, S Zhao and M Andreeff Department of Hematology, Section of Experimental Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Previous reports suggest that resistance to mitoxantrone in dif- protein is particularly important because it confers cross-resist- ferent tumor cell lines is unrelated to the overexpression of p- ance to several structurally unrelated drugs.9 The mechanisms glycoprotein. In order to determine the role of p-glycoprotein in the cellular pharmacology of mitoxantrone flow cytometry of action of mitoxantrone resistance are not well known. and confocal microscopy were used to study two human Although mitoxantrone seems to select for a unique drug- myeloid leukemia cell lines selected for resistance to mitoxan- resistance phenotype, some cross-resistance with anthracy- trone (HL-60MX2) and doxorubicin (HL-60DOX). To optimize the clines has been shown in vitro.10,11 Human colon carci- detection of intracellular mitoxantrone, we determined the noma,12 leukemia13 and gastric carcinoma14 cell lines selec- maximum excitation (607 nm) and emission (684 nm) wave- length by fluorescence spectroscopy. The modified flow cyto- ted by continuous exposure to increasing concentrations of metric conditions using 568.2 nm laser emission for excitation mitoxantrone had no p-glycoprotein overexpression. Clinical and a 620 nm long pass filter for fluorescence collection cross-over studies have not demonstrated complete cross- resulted in a 1-log increase in sensitivity, compared with stan- resistance between mitoxantrone and doxorubicin,15,16 pro- dard 488-nm laser excitation.
    [Show full text]
  • Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology
    Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology Rachael R. Schulte and Richard H. Ho Department of Pediatrics, Division of Pediatric Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN (R.R.S., R.H.H.) Downloaded from molpharm.aspetjournals.org at ASPET Journals on September 28, 2021 1 Molecular Pharmacology Fast Forward. Published on February 19, 2019 as DOI: 10.1124/mol.118.114314 This article has not been copyedited and formatted. The final version may differ from this version. MOL # 114314 OATPs and Cancer Pharmacology Corresponding Author: Richard H. Ho, MD MSCI 397 PRB 2220 Pierce Avenue Vanderbilt University Medical Center Nashville, Tennessee 37232 Downloaded from Tel: (615) 936-2802 Fax: (615) 875-1478 Email: [email protected] molpharm.aspetjournals.org Number of pages of text: 24 Number of tables: 3 Number of figures: 1 References: 204 at ASPET Journals on September 28, 2021 Number of words: Abstract: 201 Introduction: 1386 Discussion: 7737 ABBREVIATIONS: ASBT, apical sodium dependent bile acid transporter; AUC, area under the plasma time:concentration curve; BCRP, breast cancer related protein; BSP, bromosulfophthalein; CCK-8, cholecystokinin octapeptide; DHEAS, dehydroepiandrosterone sulfate; DPDPE, [D-penicillamine2,5] enkephalin; E2G, estradiol-17ß-glucuronide; E3S, estrone-3-sulfate; ENT, equilibrative nucleoside transporter; GCA, glycocholate; HEK, human embryonic kidney; IVS, intervening sequence (notation for intronic mutations); LD, linkage disequilibrium; MATE, multidrug and toxic compound extrusion; MCT, monocarboxylate 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions with Minimal Toxicity
    CLINICAL TRIALS AND OBSERVATIONS Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity Vikram Mathews, Biju George, Kavitha M. Lakshmi, Auro Viswabandya, Ashish Bajel, Poonkuzhali Balasubramanian, Ramachandran Velayudhan Shaji, Vivi M. Srivastava, Alok Srivastava, and Mammen Chandy Arsenic trioxide, as a single agent, has of 25 months (range: 8-92 months), the men was administered on an outpatient proven efficacy in inducing molecular remis- 3-year Kaplan-Meier estimate of EFS, DFS, basis. Single-agent As2O3, as used in this -sion in patients with acute promyelocytic and OS was 74.87% ؎ 5.6%, 87.21% ؎ series, in the management of newly diag leukemia (APL). There is limited long- 4.93%, and 86.11% ؎ 4.08%, respectively. nosed cases of APL, is associated with term outcome data with single-agent Patients presenting with a white blood responses comparable with conventional As O in the management of newly diag- cell (WBC) count lower than 5 ؋ 109/L and chemotherapy regimens. Additionally, this 2 3 nosed cases of APL. Between January a platelet count higher than 20 ؋ 109/L at regimen has minimal toxicity and can be have an excel- administered on an outpatient basis after ([%30.6] 22 ؍ to December 2004, 72 newly diag- diagnosis (n 1998 nosed cases of APL were treated with a lent prognosis with this regimen (EFS, remission induction. (Blood. 2006;107: regimen of single-agent As2O3 at our cen- OS, and DFS of 100%). The toxicity pro- 2627-2632) ter. Complete hematologic remission was file, in the majority, was mild and revers- achieved in 86.1%.
    [Show full text]
  • Practical Aspects of the Use of Intrathecal Chemotherapy
    Farmacia Hospitalaria ISSN: 1130-6343 ISSN: 2171-8695 Aula Médica Ediciones (Grupo Aula Médica S.L.) Practical aspects of the use of intrathecal chemotherapy Olmos-Jiménez, Raquel; Espuny-Miró, Alberto; Cárceles-Rodríguez, Carlos; Díaz-Carrasco, María Sacramento Practical aspects of the use of intrathecal chemotherapy Farmacia Hospitalaria, vol. 41, no. 1, 2017 Aula Médica Ediciones (Grupo Aula Médica S.L.) Available in: http://www.redalyc.org/articulo.oa?id=365962303008 DOI: 10.7399/fh.2017.41.1.10616 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative REVISIONES Practical aspects of the use of intrathecal chemotherapy Aspectos prácticos de la utilización de quimioterapia intratecal Raquel Olmos-Jiménez 1 Universidad de Murcia, Spain Alberto Espuny-Miró 1 Universidad de Murcia, Spain Carlos Cárceles-Rodríguez 1 Universidad de Murcia, Spain María Sacramento Díaz-Carrasco 2 Hospital Clínico Universitario Virgen de la Arrixaca, Spain Farmacia Hospitalaria, vol. 41, no. 1, Abstract 2017 Introduction: Intrathecal chemotherapy is frequently used in clinical practice for treatment and prevention of neoplastic meningitis. Despite its widespread use, there is Aula Médica Ediciones (Grupo Aula Médica S.L.) little information about practical aspects such as the volume of drug to be administered or its preparation and administration. Received: 28 July 2016 Accepted: 15 October 2016 Objective: To conduct a literature review about practical aspects of the use of intrathecal chemotherapy. DOI: 10.7399/.2017.41.1.10616 Materials: Search in PubMed/ Medline using the terms “chemotherapy AND intrathecal”, analysis of secondary and tertiary information sources. CC BY-NC-ND Results: e most widely used drugs in intrathecal therapy are methotrexate and cytarabine, at variable doses.
    [Show full text]
  • Package Leaflet: Information for the Patient Mitoxantrone 2 Mg/Ml
    Package leaflet: Information for the patient Mitoxantrone 2 mg/ml concentrate for solution for infusion Mitoxantrone Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Mitoxantrone 2 mg/ml solution is and what it is used for 2. What you need to know before you use Mitoxantrone 2 mg/ml solution 3. How to take Mitoxantrone 2 mg/ml solution 4. Possible side effects 5. How to store Mitoxantrone 2 mg/ml solution 6. Contents of the pack and other information 1. What Mitoxantrone 2 mg/ml solution is and what it is used for Mitoxantrone 2 mg/ml solution belongs to the group of medicines known as antineoplastic or anti-cancer drugs. It also belongs to the subgroup of anti-cancer medicines called anthracyclines. Mitoxantrone 2 mg/ml solution prevents cancer cells from growing, as a result of which they eventually die. The medicine also supresses the immune system and is used because of this effect to treat a specific form of multiple sclerosis when there are no alternative treatment options. Mitoxantrone 2 mg/ml is used in the treatment of: Advanced stage (metastatic form) of breast cancer. A certain of lymph node cancer (non-Hodgkin’s lymphoma).
    [Show full text]